India’s Deal Street Heats Up: Claris, Otsuka, Mitsui In JV To Tap Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
The new company will leverage manufacturing and product development competencies to reach out to emerging markets.
You may also be interested in...
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
Report says aggressive enforcement in recent years has forced capacity offline, which led to shortages.
Japan's Mitsui Acquires Stake In India's Arch Pharma For Direct Presence In The "Global Factory"
HYDERABAD, India - After Japanese drug giants Daiichi Sankyo, Eisai, Astellas and Takeda, it is the turn of Mitsui - one of the largest and most diverse Japanese industry conglomerates - to evince a direct interest in the Indian pharmaceutical industry
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.